Abstract
Background
Early treatment with sumatriptan tablets (50 and 100 mg) has been shown to be effective in retrospective and prospective study designs. Despite the efficacy of sumatriptan 50 mg and early intervention, however, some patients continue not to respond completely to this dose. New evidence with a scientific basis for early intervention suggests that some patients may need to treat early to prevent the establishment of central sensitization. Also, patients cite complete pain relief as the most important attribute of a migraine medication.
Objective
The primary objective of this study was to determine the 2-hour efficacy of sumatriptan 100 mg in achieving complete pain relief in patients with a history of nonresponse to sumatriptan 50 mg in an early-intervention treatment paradigm. Secondary end points included complete pain relief at 4 hours, consistency of complete relief in at least 2 of 3 attacks, sustained complete relief over 24 hours, satisfaction with the 100-mg dose, and relief of associated symptoms.
Methods
This open-label, prospective study was conducted at the Wesley Headache Clinic (Memphis, Tennessee). Male and female patients between the ages of 18 and 65 years who fulfilled International Headache Society classification criteria for migraine, and who had a documented history of nonresponse to sumatriptan 50 mg at 2 hours after dosing when treating in the early, mild-pain phase in at least 2 of 3 migraine attacks were eligible for the study. Patients were instructed to receive one 100-mg sumatriptan tablet at the earliest sign of pain, while still mild, in 3 subsequent migraine attacks. After each treated attack, patients were to record a detailed diary entry.
Results
Twenty patients (17 women, 3 men; mean age, 44 years) treated all 3 migraines during the early, mild-pain phase and completed the study. Of the 60 attacks treated, 48 (80%) were pain free at 2 hours, 56 (93%) were pain free at 4 hours, and 45 (75%) were pain free at 2 hours and continued to be pain free at 24 hours (sustained pain-free response). Sumatriptan 100 mg was well tolerated; none of the patients reported any adverse events.
Conclusions
In this study of migraineurs with a history of nonresponse to sumatriptan 50 mg at 2 hours after dosing in the early, mild-pain phase of migraine, increasing the dose of sumatriptan from 50 mg to 100 mg in the early-intervention paradigm, in most attacks complete pain relief was achieved for up to 24 hours. Because patients have indicated that becoming pain free was their therapeutic goal, based on the results of this study, physicians may want to consider increasing the dose of sumatriptan to 100 mg at the first sign of pain if the patient has consistently not responded to sumatriptan 50 mg in the early-intervention model.
Keywords: early intervention, nonresponders, migraine, sumatriptan
Full Text
The Full Text of this article is available as a PDF (378.7 KB).
Footnotes
This research was presented in part at the 45th Annual Scientific Meeting of the American Headache Society, Chicago, Illinois, June 19–22, 2003.
References
- 1.Pfaffenrath V, Cunin G, Sjonell G, Prendergast S. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: Defining the optimum doses of oral sumatriptan. Headache. 1998;38:184–190. doi: 10.1046/j.1526-4610.1998.3803184.x. [DOI] [PubMed] [Google Scholar]
- 2.Lipton RB, Stewart WF, Cady R. Sumatriptan for the range of headaches in migraine sufferers: Results of the Spectrum Study. Headache. 2000;40:783–791. doi: 10.1046/j.1526-4610.2000.00143.x. [DOI] [PubMed] [Google Scholar]
- 3.Cady RK, Lipton RB, Hall C. Treatment of mild headache in disabled migraine sufferers: Results of the Spectrum Study. Headache. 2000;40:792–797. doi: 10.1046/j.1526-4610.2000.00144.x. [DOI] [PubMed] [Google Scholar]
- 4.Cady RK, Sheftell F, Lipton RB. Effect of early intervention with sumatriptan on migraine pain: Retrospective analyses on data from three clinical trials. Clin Ther. 2000;22:1035–1048. doi: 10.1016/s0149-2918(00)80083-1. [DOI] [PubMed] [Google Scholar]
- 5.Winner P, Mannix LK, Putman DG. Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studies. Mayo Clin Proc. 2003;78:1214–1222. doi: 10.4065/78.10.1214. [DOI] [PubMed] [Google Scholar]
- 6.Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: A race against the development of central sensitization. Ann Neurol. 2004;55:27–36. doi: 10.1002/ana.10785. [DOI] [PubMed] [Google Scholar]
- 7.Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: A race against the development of cutaneous allodynia. Ann Neurol. 2004;55:19–26. doi: 10.1002/ana.10786. [DOI] [PubMed] [Google Scholar]
- 8.Lipton RB, Stewart WF. Acute migraine therapy: Do doctors understand what patients with migraine want from therapy? Headache. 1999;39(Suppl 2):520–526. [Google Scholar]
- 9.Tfelt-Hansen P, Block G, Dahlof C, for the International Headache Society Clinical Trials Subcommittee Guidelines for controlled trials of drugs in migraine: Second edition. Cephalalgia. 2000;20:765–786. doi: 10.1046/j.1468-2982.2000.00117.x. [DOI] [PubMed] [Google Scholar]
- 10.Dowson AJ, Ashford EA, Prendergast S, for the Sumatriptan Tablets S2CM10 Study Group Patient-selected dosing in a six-month open-label study evaluating oral sumatriptan in the acute treatment of migraine. Int J Clin Pract Suppl. 1999;105:25–33. [PubMed] [Google Scholar]
- 11.Mathew NT, Kailasam J, Gentry P, Chernyshev O. Treatment of nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: A comparative open trial. Headache. 2000;40:464–465. doi: 10.1046/j.1526-4610.2000.00069.x. [DOI] [PubMed] [Google Scholar]
- 12.Headache Classification Committee of the International Headache Society The International Classification of Headache Disorders, Cranial Neuralgias, and Facial Pain. Cephalalgia. 1988;8(Suppl 7):1–96. [PubMed] [Google Scholar]
- 13.Kosinski M, Bjorner JB, Bayliss MS. Measuring the impact of migraine and severe headache with the Headache Impact Test: Using item response theory (IRT) models to score widely-used measures of headache impact and assess disability due to migraine or other severe headaches. Neurology. 2000;54(Suppl 3):A453. Abstract S71.004. [Google Scholar]